Drug Profile
Crenolanib - AROG Pharmaceuticals/Pfizer
Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besilate; Crenolanib besylate; IND 112201Latest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer AROG Pharmaceuticals; University of Ulm
- Class Antineoplastics; Benzimidazoles; Piperidines; Quinolines; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
- Phase II Glioblastoma; Non-small cell lung cancer
- No development reported Gastric cancer; Glioma; Oesophageal cancer; Soft tissue sarcoma; Systemic mastocytosis
Most Recent Events
- 18 Dec 2023 AROG Pharmaceuticals completes a phase II trial in Acute myeloid leukaemia in USA (NCT02400255)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Gastric-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Oesophageal-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)